Jeffrey C. Gildersleeve
Center for Cancer Research
National Cancer Institute
United States of America
Jeff Gildersleeve obtained his B.S. degree in biology in 1993 from the University of California at San Diego. He obtained his Ph.D. degree in organic chemistry at Princeton University under the guidance of Professor Dan Kahne, and completed postdoctoral training with Professor Peter Schultz at The Scripps Research Institute. He began his independent career at the National Cancer Institute in 2003 and is currently a Senior Investigator in the Chemical Biology Laboratory. The Gildersleeve group uses chemical approaches and glycan microarray technology to study the roles of anti-carbohydrate immune responses in the development, progression, and treatment of cancer and HIV. Dr. Gildersleeve is a recipient of the 2006 NCI Director’s Innovation Award and the 2011 David Y. Gin New Investigator Award from the Division of Carbohydrate Chemistry of the American Chemical Society. He also serves on the Editorial Advisory Board of ACS Central Science, the Editorial Board of the Journal of Biological Chemistry, the Editorial Board of Cell Chemical Biology and the Scientific Advisory Board of the Canadian Glycomics Network.
glycan array technology, cancer biomarkers, cancer vaccines, anti-glycan antibodies, synthesis of carbohydrate antigens
Muthana SM, Gulley JL, Hodge JW, Schlom J, Gildersleeve JC. ABO blood type correlates with survival on prostate cancer vaccine therapy. Oncotarget. 2015 Oct 13;6(31):32244.
Xia L, Schrump DS, Gildersleeve JC. Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins. Cell chemical biology. 2016 Dec 22;23(12):1515-25.
Sterner E, Peach ML, Nicklaus MC, Gildersleeve JC. Therapeutic Antibodies to Ganglioside GD2 Evolved from Highly Selective Germline Antibodies. Cell Reports. 2017 Aug 15;20(7):1681-91.